Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 8/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723697 | 0.86 | CYP1A2 (0.33) | CYP1A2CYP2C19LMNATP53 | |
| SCHEMBL18854111 | 0.84 | LMNA (0.34) | CYP1A2CYP2C19LMNAGAAALDH1A1 | |
| SCHEMBL18328205 | 0.81 | CYP1A2 (0.41) | CYP1A2CYP2C19LMNATP53GAA | |
| SCHEMBL15723784 | 0.77 | HTR2A (0.31) | — | |
| SCHEMBL15724392 | 0.76 | LMNA (0.45) | CYP1A2CYP2C19LMNATP53GAA | |
| SCHEMBL14375489 | 0.76 | LMNA (0.49) | CYP1A2CYP2C19LMNAGAAALDH1A1 | |
| SCHEMBL14555480 | 0.75 | LMNA (0.31) | CYP1A2LMNAGAAGRIA2CYP2C9 | |
| SCHEMBL14555334 | 0.75 | PTGS2 (0.33) | CYP1A2LMNAGAAGRIA2CYP2C9 | |
| SCHEMBL20725338 | 0.74 | LMNA (0.50) | CYP1A2CYP2C19LMNAGAAALDH1A1 | |
| SCHEMBL15723804 | 0.74 | LMNA (0.50) | CYP1A2CYP2C19LMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | CYP1A2 489/4885CYP2C19 386/4885LMNA 3182/4885 |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | CYP1A2 782/4885CYP2C19 391/4885LMNA 3258/4885 |
| US-10202353-B2 | Therapeutic compounds | RPL35, SARS1, HAVCR2 | CYP1A2 903/4885CYP2C19 575/4885LMNA 3179/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CYP1A2 489/4885CYP2C19 386/4885LMNA 3182/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CYP1A2 489/4885CYP2C19 386/4885LMNA 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.